Descripción del proyecto
Tomografía por resonancia magnética nuclear metabólica para el diagnóstico de enfermedades cardiovasculares
La caracterización molecular de los tejidos es necesaria para comprender la fisiopatología de las enfermedades. La tomografía por emisión de positrones (PET) es la única modalidad de obtención de imágenes que mide la actividad metabólica de las células en los tejidos, pero no es adecuada para comprender y caracterizar enfermedades cardiovasculares. Para abordar esta limitación, el proyecto MetaboliQs, financiado con fondos europeos, ha desarrollado un método novedoso de tomografía por resonancia magnética nuclear que proporciona información sobre el estado químico del tejido. El método amplifica por mil la señal de los metabolitos, generando información importante sobre la actividad metabólica por una fracción del coste. Se espera que el método de MetaboliQs libere capacidades de diagnóstico novedosas e impulse los tratamientos personalizados de las enfermedades cardiovasculares y otras enfermedades metabólicas.
Objetivo
Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: more people die annually from CVDs than from any other cause. Despite emerging diagnostics tools and therapeutics, several areas of significant unmet need remain unaddressed among CVD patients. The ability to personalize cardiovascular medical care and improve outcomes, will require characterization of disease processes at a molecular level. The current state-of-the-art, e.g. Positron emission tomography (PET), does not provide detailed information about the chemical state of the tissue at a molecular level, therefore it remains difficult to accurately diagnose and confidently select appropriate therapy in many circumstances. The MetaboliQs project brings together two areas of European excellence - diamond-based quantum sensing and medical imaging. We will translate a newly developed hyperpolarization method for magnetic resonance imaging (MRI) based on the quantum dynamics of nitrogen-vacancy (NV) centers. This breakthrough quantum technology will enable previously unachievable, highly sensitive quantification of metabolic activity, paving the way for precision diagnostics and better personalized treatment of cardiovascular and other metabolic diseases. For realizing and eventually commercializing the technology, MetaboliQs brings together a world-class multidisciplinary consortium with end to end expertise - leading diamond quantum technology research institutes (Fraunhofer IAF - quantum-grade diamond growth and fabrication, HUJI - quantum sensing) and innovative companies (Element 6 - worldwide leader in synthetic diamonds, NVision - inventor of diamond-based polarization), as well as two expert users of hyperpolarized and cardiovascular MRI (TUM, ETH Zurich - first in continental Europe to conduct clinical trials of hyperpolarized MRI for cardiovascular disease) and the market leader in electron paramagnetic resonance and preclinical MRI (Bruker).
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-FETFLAG-2018-03
Régimen de financiación
RIA - Research and Innovation actionCoordinador
80686 Munchen
Alemania